TheraRadar
Clinical-Stage Companies / Apnimed

Apnimed

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/2/2025

14
Total Trials
3
Phase 3
11
Phase 2
1
Recruiting
136
Score

Pipeline by Phase

Phase 3
3
Phase 2
11
Phase 1
1

Therapeutic Focus

Obstructive Sleep Apnea OSA Sleep Apnea Hypertension OSA - Obstructive Sleep Apnea

Clinical Trials (14)

NCT05813275 Phase 3 COMPLETED

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

Started: 9/16/2023

NCT05811247 Phase 3 COMPLETED

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

Started: 8/28/2023

NCT06566820 Phase 3 ENROLLING BY INVITATION

Continuation Protocol for Obstructive Sleep Apnea (OSA)

Started: 7/3/2024

NCT06776432 Phase 2 RECRUITING

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

Started: 4/2/2025

NCT06400615 Phase 2 COMPLETED

Study That Tests AD109 in Patients Taking GLP-1 Drugs

Started: 5/20/2024

NCT05793684 Phase 2 COMPLETED

AD816 Crossover Study

Started: 4/28/2023

NCT04445688 Phase 2 COMPLETED

Crossover Trial of AD036 in Obstructive Sleep Apnea

Started: 7/15/2020

NCT04905979 Phase 2 COMPLETED

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Started: 7/31/2021

NCT04580394 Phase 2 COMPLETED

Crossover Trial of AD109 in Obstructive Sleep Apnea

Started: 10/27/2020

NCT03845023 Phase 2 COMPLETED

Trial of AD036 in Obstructive Sleep Apnea

Started: 3/7/2019

NCT04631107 Phase 2 COMPLETED

AD109 Dose Finding in Mild to Moderate OSA

Started: 12/22/2020

NCT05071612 Phase 2 COMPLETED

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Started: 11/29/2021

NCT04645524 Phase 2 COMPLETED

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Started: 12/1/2020

NCT05101122 Phase 1 COMPLETED

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

Started: 10/19/2021

Drug Candidates

AD109 Placebo Sivopixant Acetazolamide SASS-001 Aroxybutynin and Atomoxetine Period A Period B Period C AD036
Activity Status: Slowing
Last Trial Started: 4/2/2025
Last Trial Ended: 5/7/2025
Trials (12 months): 0
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.